In 2017, the review of the Patient-Centered Outcomes Research Trust Fund will determine the adequacy and the use of funding and there are 3 ways to measure performance in patient-centered outcomes research.
In 2017, the review of the Patient-Centered Outcomes Research Trust Fund will determine the adequacy and the use of funding to determine whether levels should be adjusted in autumn 2019. And now researchers are analyzing work in patient-centered outcomes research to ascertain how well the work is being done and what might be done better, according to a new commentary from RAND.
The Patient-Centered Outcomes Research Institute, established in 2010, has funded hundreds of studies and Thomas W. Concannon, senior policy researcher at RAND, highlights 3 ways to measure performance in patient-centered outcomes research:
Read the full commentary at RAND.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More